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ARTHUR J. TRONSTEIN M.D.**
While certain of the oxyquinoline derivatives, such as Vioform and Quinolor
Compound, have been known to be useful as topical therapeutic agents in pyo-
dermas and related conditions, the dichioroxyquinaldine products are not so well
known in this country. This compound, commonly known as Sterosan, has been
studied by European workers, and Sulzberger (1) has also suggested that it may
have merit. In the European literature Hotz and Frutiger (2), Jadassohn et al. (3),
Jadassohn and Fazler (4), Bruni (5), and Hirsch (6) have all reported upon its
use as a therapeutic agent in dermatologic conditions due to infection.
CHEMICAL NATURE OF DICHLOROXYQUINALDINE
The "parent" chemical of this material is oxyquinolin. This chemical has long
been known to have some bactericidal value. Its action is most effective upon
staphylococcus. Viol orm, 5 chloro 7 iodo hydroxyquinoline, is much more effec-
tive than is oxyquinoline. However, it has been known to occasionally produce
local irritation or sensitization effects. Jadassohn believed these side effects
might be due to its iodine content. The well-known Quinolor Compound is a mix-
ture of three closely related substances; 5 chior 8 hydroxyquinoline, 7 chior 8
hydroxyquinoline, and 5,7, dichlor 8 hydroxyquinoline. Quinolor Compound is
also an effective bacteriostatic agent.
The replacement of one hydrogen in hydroxyquinoline by a methyl radical pro-
duces oxyquinaldine, a rather ineffective bacteriostatic agent. The dichloroxy-
quinaldine products have been shown to be decidedly efficient bacteriostatic
products, especially against actively reproducing Gram positive organisms.
PROPERTY OF SENSITIZATION
No detailed studies concerning sensitization to this material appear in the
literature, to our knowledge. For our preliminary work we used the routine 48
hour patch test. These 48 hour tests were followed, whenever possible, by a
repetitive patch test method now under study by the Department of Dermatol-
ogy and Syphilology of the University of Cincinnati. Results of the various tests
are shown in the following tables.
The single patient showing a doubtful reaction to the 5% ointment used for
the tests showed a negative reaction to tests with the 5% powder and 5% paste
forms. No bases alone were available for control use. Repetitive tests upon the
same sites were also negative.
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The single doubtful reaction has been noted before. The above tables do not in-
clude such experiences as developed in clinical use. Whenever sensitivity was sus-
pected, every effort was made to verify it, but we have not as yet seen proven
eczematous sensitization to the material.
Clinically, we found evidence of irritation in a young colored girl suffering
from chronic discoid lupus erythematosus with secondary infection of one lesion.
The ointment gave excellent results as far as the infection was concerned, but
seemed to irritate the lupus erythematosus to a moderate degree. Patch tests
gave negative results, and further use upon a non-infected lesion made no changes
whatsoever.
TABLE 1
1esults of routine 48 hour patch tests
NO. PATIENTS + U
111 0 1 110
TABLE 2
Results of repetitive patch testing
METHOD 50. PTS.
26
66
4
7
6
0
25
66
4
7
6
1
0
0
0
0
+
0
0
0
0
0
Tested q. 48 hrs.—same site 4 times in approx.
21 days
Tested as above, but not within 21 days
Tested q. 48 hrs. 3 times in same site
Tested as above 2 times
Routine 48 hr. only
Totals 111 110 1 o
A local physician with nummular eczema reported by Goldman (7) was patch
tested and showed a strong reaction to Vioform, but a negative reaction to 3
per cent iodine in carbowax and a negative reaction to dichioroxyquinaldine.
Goldman also reports a patient with marked contact dermatitis of the hands
who gave strongly positive reactions to Vioform and to 1 per cent iodine solu-
tion, but a negative patch test reaction to this material. In three other patients
with eczematous dermatitis of the hands dichloroxyquinaldine could be used
where Vioform could not be tolerated. In these patients no patch tests were done.
In a few instances some "grease reactions" were noted. "Grease reactions" are
seen often in stasis dermatitis, and are interpreted as vesicular flare ups due to
increased surface temperature. These are not oil folliculitis of the skin nor eczem-
atous reactions by the greases.
CLINICAL RESULTS
The materials used were employed in three forms: a bland ointment whose
base is essentially a petrolatum and beeswax type; a water miscible paste whose
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base is essentially triethanolamine, wool fat, and talcum, and a powder form
with zinc oxide and talcum as essential components. The full formulae for these
bases has not been stated by the manufacturer. In each preparation, there was a
5 per cent concentration of the active ingredient.
For the most part we selected cases in which no prior therapy had been em-
ployed. Some were cases in which prior therapy had failed. A few of the patients
had been treated before for similar conditions, and had suffered recurrences. In
TABLE 3
DIAGNOSIS
CLINICAL RLSULTS
No. Pts.
Cured or Improved
markedly but not
improved cured
No change
Worse
under
therapy
Impetigo
Superficial pyoderma, ecthyma, etc
Sycosis vulgaris
Psoriasis
Infected acne
Infectious eczematoid dermatitis
Diaper dermatitis, folliculitis
Infected neurodermatitis
Infected lower leg ulcer syndrome
Infected superficial mycoses
Pompholyx
Infected seborrhea
Conjunctivitis
Infected lupus erythematosus
Impetiginized factitia
Pemphigus vulgaris
Infected ivy dermatitis
Infected scabies
Nodular periphiebitis with ulceration...
Perleche
Pruritus ani
Dermatitis herpetiformis
Unclassified
49
36
3
3
5
28
9
5
16
24
2
8
4
2
4
1
5
3
2
3
4
2
8
47
33
2
0
0
9
9
0
8
13
0
2
3
0
0
0
5
0
0
2
0
0
2
2
2
1
1
0
16
0
5
6
7
0
2
1
0
4
0
0
3
0
1
2
0
5
0
1
0
2
1
2
0
0
2
2
2
4
0
2
4
1
0
0
2
0
1
2
1
0
0
0
0
2
1
0
0
0
2
0
0
0
0
0
0
0
0
0
0
1
0
0
Totals, 23 types 224 135
60%
61
27%
22
10%
6
3%
some instances we used "rightist-leftist" methods for comparison. This method
is one in which one extremity is treated with one mode of therapy while the other
extremity, having lesions of similar intensity, is treated by a different method,
and results compared. In no cases were systemic agents such as sulfonamides,
antibiotics, etc., used, nor were any physical agents, radiations, etc., employed
while the patients were under therapy with this material.
If the product seemed to be ineffective within a reasonably short time (6—7
days), all therapy was discontinued for several days before beginning any other
form of treatment. Occasionally, in order to satisfy the patient, we used a placebo
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during this interval. This waiting period would be of value to judge any latent
results, and would give a better chance for comparison of results of the next form
of treatment.
It is evident that those dermatitides caused entirely by, or aggravated by
pyogenic infection had excellent response to Sterosan.
As has been stated before, any case in which we suspected sensitization or local
irritation to be taking place, was carefully studied by patch tests. No proved
cases of these reactions were found. In an occasional instance we felt that the
apparent aggravation of symptoms was due to the "grease reaction" from the
base.
When controlled comparison with other therapeutic agents, such as penicillin
ointment (500 U/Gm.), 2—5% ammoniated mercury ointment, 5% boric acid
ointment, etc., could be made, the results were very favorable. Comparison of
results between the various forms (ointment, paste and powder) did not show
any particular variation.
In a few cases we used the material simply as an anti-pruritic agent. Results
were inconclusive. Whatever relief was obtained could well have been attributed
to the base material as well as to the active ingredient. No work was done com-
bining the agent with such medicaments as tar, phenol, salicylic acid, etc., but
we see no reason why this could not be done.
No pigmentary changes were noted following its use on the skin, but when used
on the blonde hair of one child, slight discoloration was claimed by the parents.
In this case, other factors may have been present and may have produced the
discoloration. Simple tests upon linens, clothing, etc., do not indicate any harm-
ful effects. The ointment is a tan color, but is easily removed from clothing by
the usual laundry methods. The other mixture forms are white in color.
CONCLUSIONS
Dichioroxyquinaldine (Sterosan) appears to be a satisfactory addition to the
field of topical therapy in dermatology. Its usefulness is greatest when employed
in those conditions in which infection by Gram positive, actively reproducing
microorganisms is the specific etiological agent, or where such infection plays a
major role. It offers adequate bacteriostatic action in most of such cases with
little or no evidence of serious side reactions.
In our experience it appeared to be less sensitizing than a related oxyquinoline
derivative, 5 chlor 7 iodo 8 hydroxyquinoline (Viol orm).
Further study of dichloroxyquinaldine and related compounds seems indicated.
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